Answer
Canakinumab (Ilaris) is contraindicated in patients with hypersensitivity to canakinumab or any excipient listed in section 6.1, or with active, severe infections.
Sources for this answer
- Ilaris 150mg/ml Solution for InjectionNovartis Pharmaceuticals UK Ltd · emc · SmPC §4.3 Contraindications · Version 8Document updated
Sources checked